olaparib,abiraterone,talazoparib,enzalutamide
merck,astellas,astrazeneca,pfizer
['talapro-2', 'crpc', 'propel', 'prostate', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'biomarker']
talapro-2 showed good results in rpfs; os still immature. propel os sub-analysis in non hrd group was underwhelming. great discussion by elena castro. exciting prostate day at #gu23 biomarkers or not biomarkers? hot topic in mcrpc. what do we think? 
Assistant Professor, Urologic Sciences Dpt, University of British Columbia, Medical Oncologist BC Cancer, Senior Research Scientist Vancouver Prostate Centre